How might we maximize the therapeutic efficiency of levodopa? Parkinson’s disease is a disease of dopamine deficiency in the brain. You can’t just have people take dopamine, because it can’t pass through the blood-brain barrier. But you can give people a dopamine precursor called levodopa, or L-dopa, which can get up into the brain and be turned into dopamine. However, with prolonged treatment, the patients start to show a reduced response to levodopa. After five years of levodopa treatment, the benefits start wearing off before the next dose, or don’t completely contain symptoms in a substantial proportion of patients, and represents a major source of disability and significantly impairs quality of life. Therefore, maximizing the therapeutic efficiency of levodopa is an important goal, and that’s where protein-restricted diets come in. Wait, what does protein have to do with Parkinson’s?…
-
Recent Posts
-
Archives
- May 2025
- April 2025
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- September 2013
- July 2013
- March 2013
- January 2013
- December 2012
- November 2012
- December 1
-
Meta